Imugene Limited (IUGNF)

0.0900 +0.0017 (+1.94%) At close: 12:43PM EDT

Imugene Limited

4-6 Bligh Street
Suite 12.01 Level 12
Sydney, NSW 2000
Australia

https://www.imugene.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD	Exec. Chairman	235.04k	N/A	1956
Ms. Leslie Chong	CEO, MD & Exec. Director	715.99k	N/A	N/A
Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D.	Chief Technology Officer	284.05k	N/A	N/A
Dr. Monil Shah M.B.A., Pharm.D.	Chief Bus. Officer	551.83k	N/A	N/A
Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD	CFO & Company Sec.	N/A	N/A	1967
Ms. Ursula McCurry	Sr. VP of Clinical Operations	N/A	N/A	N/A
Dr. Giovanni Selvaggi	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Corporate Governance

Imugene Limited’s ISS Governance QualityScore as of March 30, 2023 is 9. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.